Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Karuna Therapeutics (KRTX)
NASDAQ:KRTX
Holding KRTX?
Track your performance easily
KRTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$158.38 - $329.99
Previous Close$329.83
Volume85.75K
Average Volume (3M)1.01M
Market Cap
$12.60B
Enterprise Value$11.27B
Total Cash (Recent Filing)$1.34B
Total Debt (Recent Filing)$15.61M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
May 02, 2024EPS Estimate
-$2.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.73
Shares Outstanding38,147,652
10 Day Avg. Volume738,652
30 Day Avg. Volume1,011,635
Standard Deviation0.58
R-Squared0.01
Alpha0.10
Financial Highlights & Ratios
Price to Book (P/B)10.03
Price to Sales (P/S)1182.88
Price to Cash Flow (P/CF)-28.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue25.56K
Enterprise Value/Gross Profit1.06K
Enterprise Value/Ebitda-25.89
Forecast
1Y Price Target
$330.00Price Target Upside0.06% Upside
Rating ConsensusHold
Number of Analyst Covering15
Karuna Therapeutics News
PremiumCompany Announcements
Karuna Therapeutics Undergoes Extensive Corporate Transformation
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
KRTX FAQ
What was Karuna Therapeutics’s price range in the past 12 months?
Karuna Therapeutics lowest stock price was $158.38 and its highest was $329.99 in the past 12 months.
What is Karuna Therapeutics’s market cap?
Currently, no data Available
When is Karuna Therapeutics’s upcoming earnings report date?
Karuna Therapeutics’s upcoming earnings report date is May 02, 2024 which is 207 days ago.
How were Karuna Therapeutics’s earnings last quarter?
Karuna Therapeutics released its earnings results on Feb 22, 2024. The company reported -$3.01 earnings per share for the quarter, missing the consensus estimate of -$2.65 by -$0.36.
Is Karuna Therapeutics overvalued?
According to Wall Street analysts Karuna Therapeutics’s price is currently Undervalued.
Does Karuna Therapeutics pay dividends?
Karuna Therapeutics does not currently pay dividends.
What is Karuna Therapeutics’s EPS estimate?
Karuna Therapeutics’s EPS estimate is -$2.73.
How many shares outstanding does Karuna Therapeutics have?
Karuna Therapeutics has 23,412,754 shares outstanding.
What happened to Karuna Therapeutics’s price movement after its last earnings report?
Karuna Therapeutics reported an EPS of -$3.01 in its last earnings report, missing expectations of -$2.65. Following the earnings report the stock price went up 0.138%.
Which hedge fund is a major shareholder of Karuna Therapeutics?
Among the largest hedge funds holding Karuna Therapeutics’s share is Woodline Partners LP. It holds Karuna Therapeutics’s shares valued at 113M.
---
Karuna Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$330.00 (0.06% Upside)
$330.00 (0.06% Upside)
Blogger Sentiment
Bullish
KRTX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 694.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $599.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.72%
12-Months-Change
Fundamentals
Return on Equity
-36.44%
Trailing 12-Months
Asset Growth
14.74%
Trailing 12-Months
Company Description
Karuna Therapeutics
Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company develops treatments for people afflicted with schizophrenia. Karuna Therapeutics was founded in July 2009 by Andrew Miller, Eric Elenko and Peter Jeffrey Conn and is headquartered in Boston, MA.
---
KRTX Earnings Call
Q3 2023
0:00 / 0:00
---
KRTX Stock 12 Month Forecast
Average Price Target
$330.00
▲(0.06% Upside)
Technical Analysis
Best Analysts Covering KRTX
1 Year
1 Year Success Rate
3/3 ratings generated profit
1 Year Average Return
+71.83%
reiterated a buy rating 2 years ago
Copying Esther Hong's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +71.83% per trade.
---